Blockade of the renin-angiotensin-aldosteron system (RAAS) in secondary cardiovascular prevention

Abstract

There is an evidence that ACE inhibitors decrease cardiovascular mortality and morbidity in secondary prevention. Clinical trial ONTARGET brought similar evidence also for sartan telmisartan.

Keywords

• Secondary prevention
• RAAS
• telmisartan
• ACE inhibitors